Fulcrum Therapeutics, Inc. (FULC)
| Market Cap | 285.35M -23.0% |
| Revenue (ttm) | n/a |
| Net Income | -85.00M |
| EPS | -1.21 |
| Shares Out | 76.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 980,410 |
| Open | 3.700 |
| Previous Close | 3.710 |
| Day's Range | 3.650 - 3.755 |
| 52-Week Range | 2.830 - 15.740 |
| Beta | 2.58 |
| Analysts | Hold |
| Price Target | 3.40 (-9.09%) |
| Earnings Date | Jul 30, 2026 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for FULC stock is "Hold." The 12-month stock price target is $3.4, which is a decrease of -9.09% from the latest price.
News
Fulcrum Therapeutics Quarterly report: Q2 2026
Fulcrum Therapeutics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C...
Kaplan Fox Announces a Securities Investigation into Fulcrum Therapeutics, Inc. (FULC) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "C...
Fulcrum Therapeutics downgraded to Underweight from Overweight at JPMorgan
JPMorgan double downgraded Fulcrum Therapeutics (FULC) to Underweight from Overweight without a price target citing the discontinuation of the company’s lead asset pociredir in sickle cell disease. As...
Goldman suspends rating on Fulcrum Therapeutics
Goldman Sachs suspended the firm’s rating on Fulcrum Therapeutics (FULC) after the company announed the discontinuation of its clinical program evaluating pociredir in sickle cell disease. As pociredi...
Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities la...
Fulcrum Therapeutics price target lowered to $3 from $8 at BofA
BofA lowered the firm’s price target on Fulcrum Therapeutics (FULC) to $3 from $8 and keeps an Underperform rating on the shares after the company announced the discontinuation of pociredir…
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk conce...
Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Fulcrum Therapeutics (FULC) to Market Perform from Outperform with a price target of $4, down from $24, after the company announced the discontinuation of the pociredir program in…
Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein downgraded Fulcrum Therapeutics (FULC) to Neutral from Buy with a price target of $3, down from $25. The company announced the discontinuation of its pociredir…
Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Fulcrum Therapeutics (FULC) to Market Perform from Outperform with a $4 price target
Fulcrum Therapeutics downgraded to Hold from Buy at Truist
Truist downgraded Fulcrum Therapeutics (FULC) to Hold from Buy with a price target of $4, down from $17. The company announced the discontinuation of the development of pociredir following FDA…
Piper double downgrades Fulcrum after sickle cell development stopped
Piper Sandler analyst Edward Tenthoff last night double downgraded Fulcrum Therapeutics (FULC) to Underweight from Overweight with a price target of $3, down from $23. The company is discontinuing the...
Fulcrum Therapeutics downgraded to Underweight from Overweight at Piper Sandler
Piper Sandler downgraded Fulcrum Therapeutics (FULC) to Underweight from Overweight with a price target of $3, down from $23.
Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
Stifel downgraded Fulcrum Therapeutics (FULC) to Hold from Buy with a price target of $3, down from $25. The company “surprisingly” announced it is discontinuing development of pociredir following rec...
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viable r...
Fulcrum discontinues pociredir program in SCD, initiates strategic review
Fulcrum Therapeutics (FULC) announced the discontinuation of its pociredir program for the treatment of sickle cell disease, or SCD, and the initiation of a review of strategic alternatives. On May…
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk prof...
Fulcrum Therapeutics price target raised to $8 from $7 at BofA
BofA raised the firm’s price target on Fulcrum Therapeutics (FULC) to $8 from $7 and keeps an Underperform rating on the shares. The firm updated the company’s model post the…
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of ...
Fulcrum Therapeutics Proxy statement: Proxy filing
Fulcrum Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Fulcrum Therapeutics Proxy statement: Proxy filing
Fulcrum Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Fulcrum Therapeutics Earnings Call Transcript: Q1 2026
Positive phase I-B data for pociredir in sickle cell disease showed robust HbF increases and reduced VOCs, with strong safety and a solid cash runway into 2029. A registration-enabling trial is planned for the second half of 2026, pending FDA feedback.
Fulcrum Therapeutics Earnings release: Q1 2026
Fulcrum Therapeutics released its Q1 2026 earnings on April 27, 2026, summarizing the period's financial results.
Fulcrum Therapeutics Quarterly report: Q1 2026
Fulcrum Therapeutics has published its Q1 2026 quarterly earnings report on April 27, 2026.